Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zebrafish | 15 | 2023 | 353 | 3.490 |
Why?
|
| Anemia, Aplastic | 4 | 2026 | 34 | 1.530 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 189 | 1.110 |
Why?
|
| Genome | 3 | 2023 | 417 | 1.040 |
Why?
|
| Haplotypes | 3 | 2023 | 656 | 0.930 |
Why?
|
| Zebrafish Proteins | 5 | 2016 | 159 | 0.900 |
Why?
|
| Genes, MHC Class I | 2 | 2014 | 46 | 0.810 |
Why?
|
| Hematopoiesis | 4 | 2019 | 186 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2026 | 659 | 0.640 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2024 | 977 | 0.590 |
Why?
|
| Side-Population Cells | 1 | 2019 | 1 | 0.580 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 68 | 0.550 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 105 | 0.540 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2016 | 212 | 0.540 |
Why?
|
| Cell Separation | 2 | 2017 | 200 | 0.510 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2019 | 461 | 0.480 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 89 | 0.480 |
Why?
|
| Flow Cytometry | 2 | 2017 | 720 | 0.460 |
Why?
|
| Anemia, Neonatal | 1 | 2015 | 4 | 0.460 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2015 | 3 | 0.450 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2015 | 3 | 0.450 |
Why?
|
| Pyruvate Kinase | 1 | 2015 | 13 | 0.450 |
Why?
|
| Leukemoid Reaction | 1 | 2015 | 5 | 0.440 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2015 | 17 | 0.440 |
Why?
|
| Down Syndrome | 1 | 2015 | 54 | 0.430 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 443 | 0.420 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2017 | 66 | 0.420 |
Why?
|
| Cell Differentiation | 2 | 2019 | 1646 | 0.400 |
Why?
|
| Gene Expression | 2 | 2013 | 1320 | 0.360 |
Why?
|
| Animals | 15 | 2023 | 28894 | 0.320 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1764 | 0.300 |
Why?
|
| Tretinoin | 1 | 2010 | 130 | 0.300 |
Why?
|
| Hemolysis | 1 | 2009 | 66 | 0.300 |
Why?
|
| North America | 2 | 2026 | 210 | 0.270 |
Why?
|
| Biological Evolution | 1 | 2016 | 1072 | 0.270 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2012 | 668 | 0.260 |
Why?
|
| Phylogeny | 4 | 2022 | 1339 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2010 | 682 | 0.240 |
Why?
|
| Child | 7 | 2026 | 7681 | 0.230 |
Why?
|
| Mutation | 2 | 2015 | 4392 | 0.220 |
Why?
|
| Chromosomes | 1 | 2023 | 91 | 0.190 |
Why?
|
| Child, Preschool | 2 | 2026 | 4001 | 0.180 |
Why?
|
| Major Histocompatibility Complex | 2 | 2014 | 88 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2023 | 222 | 0.180 |
Why?
|
| Hemoglobins | 2 | 2015 | 198 | 0.180 |
Why?
|
| Hematologic Diseases | 2 | 2017 | 77 | 0.180 |
Why?
|
| Receptors, Immunologic | 1 | 2022 | 142 | 0.170 |
Why?
|
| Exons | 1 | 2023 | 451 | 0.170 |
Why?
|
| Recombinational DNA Repair | 1 | 2020 | 11 | 0.160 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2015 | 330 | 0.160 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 2572 | 0.150 |
Why?
|
| Gene Editing | 1 | 2020 | 56 | 0.150 |
Why?
|
| Transcriptome | 2 | 2016 | 820 | 0.150 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 113 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2015 | 2529 | 0.140 |
Why?
|
| Animals, Genetically Modified | 2 | 2017 | 191 | 0.140 |
Why?
|
| Humans | 15 | 2026 | 98080 | 0.140 |
Why?
|
| Infant | 3 | 2017 | 3328 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2026 | 3022 | 0.130 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 21 | 0.130 |
Why?
|
| RNA Splicing | 1 | 2019 | 163 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1028 | 0.130 |
Why?
|
| Cloning, Organism | 1 | 2016 | 19 | 0.120 |
Why?
|
| Benzimidazoles | 1 | 2017 | 118 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2016 | 112 | 0.120 |
Why?
|
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 1567 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2022 | 2005 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2016 | 303 | 0.110 |
Why?
|
| Antigen Presentation | 1 | 2016 | 234 | 0.110 |
Why?
|
| Gestational Age | 1 | 2015 | 340 | 0.100 |
Why?
|
| GATA1 Transcription Factor | 2 | 2012 | 20 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 180 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 2013 | 209 | 0.100 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 220 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 177 | 0.100 |
Why?
|
| Sequence Alignment | 1 | 2013 | 353 | 0.090 |
Why?
|
| Embryo, Nonmammalian | 2 | 2012 | 204 | 0.090 |
Why?
|
| Locus Control Region | 1 | 2012 | 3 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 568 | 0.090 |
Why?
|
| Globins | 1 | 2012 | 30 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2015 | 337 | 0.090 |
Why?
|
| Genetic Linkage | 1 | 2013 | 613 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2024 | 480 | 0.080 |
Why?
|
| Chimerism | 1 | 2011 | 38 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2013 | 1061 | 0.080 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2010 | 4 | 0.080 |
Why?
|
| Female | 5 | 2026 | 51536 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 911 | 0.080 |
Why?
|
| Polyradiculoneuropathy | 1 | 2009 | 8 | 0.080 |
Why?
|
| Models, Animal | 1 | 2011 | 279 | 0.080 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2009 | 26 | 0.080 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 306 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 2896 | 0.070 |
Why?
|
| Neoplasm Transplantation | 1 | 2010 | 399 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2011 | 388 | 0.070 |
Why?
|
| Male | 3 | 2026 | 47076 | 0.070 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 849 | 0.070 |
Why?
|
| Neoplasms | 1 | 2023 | 3334 | 0.070 |
Why?
|
| Models, Genetic | 1 | 2013 | 1005 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 860 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2006 | 14 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 566 | 0.060 |
Why?
|
| Antirheumatic Agents | 1 | 2006 | 65 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2558 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 2023 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 259 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 137 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2023 | 177 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2022 | 123 | 0.040 |
Why?
|
| Fetal Hemoglobin | 1 | 2021 | 13 | 0.040 |
Why?
|
| Adolescent | 2 | 2015 | 10080 | 0.040 |
Why?
|
| Recurrence | 1 | 2024 | 1254 | 0.040 |
Why?
|
| Nitroreductases | 1 | 2020 | 5 | 0.040 |
Why?
|
| Templates, Genetic | 1 | 2020 | 31 | 0.040 |
Why?
|
| Indicators and Reagents | 1 | 2020 | 68 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 402 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 268 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2021 | 238 | 0.040 |
Why?
|
| Melanocytes | 1 | 2020 | 62 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2021 | 418 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 310 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 3620 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 257 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1110 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2015 | 38 | 0.030 |
Why?
|
| RNA | 1 | 2020 | 595 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 2013 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2555 | 0.030 |
Why?
|
| United States | 2 | 2017 | 8197 | 0.020 |
Why?
|
| NF-E2 Transcription Factor, p45 Subunit | 1 | 2012 | 1 | 0.020 |
Why?
|
| Genes, Switch | 1 | 2012 | 7 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2015 | 310 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 421 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1779 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 110 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1565 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 435 | 0.020 |
Why?
|
| Body Patterning | 1 | 2010 | 219 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 2585 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 4116 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 2002 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 79 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 103 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 6233 | 0.010 |
Why?
|
| Rituximab | 1 | 2006 | 135 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2006 | 241 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2010 | 594 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2006 | 376 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 9711 | 0.010 |
Why?
|
| Phenotype | 1 | 2010 | 2638 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1302 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 7507 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 1717 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1416 | 0.010 |
Why?
|